24 Mar 2012
Protonix has been shown to inhibit CYP450 2C19 in vitro, therefore an interaction is theoretically possible leading to reduced formation of the active metabolite of Plavix and reduced therapeutic efficacy. Product labeling for Protonix states that no dosage adjustment of Plavix is necessary when administered with an approved dosage of Protonix. However, it may be advisable to closely monitor the therapeutic efficacy of Plavix during concomitant treatment. An H2-receptor antagonist may be substituted if an interaction is suspected.
You can read the entire write-up on the interactions here: http://www.drugs.com/interactions-check.php?drug_list=705-360,1790-1152
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
... cure are accessible for a 10 yr ols girl
1 answer • 17 Jul 2010
1 answer • 28 Jun 2011
Plavix patent expired November 2011.
2 answers • 23 Feb 2012
safety point is chances of bleeding. & efficacy point is platelet aggregation inhibition in patients with Acute Coronary Syndrome after ...
1 answer • 9 May 2012